Après-demain

Après-demain is owned by Debiopharm Group.

Debiopharm Group has 3 subsidiaries including Après-demain, Debiopharm International and Debiopharm Research & Manufacturing.

They are in:

• Pharmaceuticals75%
• Biotechnology25%

View the org chart displaying its 5 main executives

Most searched biographies at Après-demain

• Thierry Mauvernay, President
• Alexandra Le Coz Sanchez, Secretary General
• Sophie Marguerat, Director, Compliance & Operations Management

Create your alert
to follow the executive moves at Après-demain.

Debiopharm Group has 2,277 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Histogen has filed for bankruptcy protection  (posted on April 19 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Après-demain

• Debiopharm to showcase research results of their DDR Inhibitors at the 2024 AACR Conference in San Diego - Debiopharm
• Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-Driven Solid Tumors - Debiopharm
• Strategikon Closes Series A1 Funding Round to Modernize Clinical Trials Business Operations Worldwide - Debiopharm
• Press Releases - Debiopharm
• TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer - Debiopharm
• Challenge pour la Qualité de vie du patient 2024, l’appel à projets est ouvert - Debiopharm
• Genialis and Debiopharm Set Up Biomarker Discovery Collaboration - Debiopharm
• MedaSystems Secures Additional Funding from Debiopharm Innovation Fund to Accelerate Global Access to Pre-approval Treatment - Debiopharm
• Debiopharm and ThinkingNodeLife.ai Forge Strategic Partnership to Propel Cancer Drug Development - Debiopharm
• Debiopharm Extends SunRock Biopharma Partnership for Antibody-Drug Conjugates Targeting HER3 in EGFR Mutated Cancers - Debiopharm
• View more press releases Close

Social media about Après-demain

• Après-demain on Wikipedia, Google News & Yahoo Finance
• Après-demain on LinkedIn, Twitter & YouTube

Contact by email its executives including Thierry Mauvernay

Call Après-demain at +41 27...

View the org chart

Register to receive your alert

Report an error